Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: A PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 162-169

  Tateno, Amane ^a   Arakawa, Ryosuke ^a   Okumura, Masaki ^a   Fukuta, Hajime ^a   Honjo, Kazuyoshi ^a   Ishihara, Keiichi ^a   Nakamura, Hiroshi ^b   Kumita, Shin Ichiro ^a   Okubo, Yoshiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

blonanserin; dopamine D2 receptor occupancy; hyperprolactinemia; positron emission tomography; schizophrenia

Indexed keywords

BLONANSERIN; DOPAMINE 2 RECEPTOR; ISOREMOXIPRIDE; ISOREMOXIPRIDE C 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DSM-IV; FEMALE; HUMAN; HYPOPHYSIS; MALE; PERMEABILITY BARRIER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; TEMPORAL CORTEX;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CASE-CONTROL STUDIES; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SCHIZOPHRENIA; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84874935839     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182825bce     Document Type: Article

References (41)

1. Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24:65-84.
2. Garcia E, Robert M, Peris F, et al. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009;23:615-625.
3. Miura S. Clinical evaluation of blonanserin for schizophrenia: a randomized study comparing blonanserin with risperidone. Jpn J Clin Psychopharmacol. 2008;11:297-314.
4. Oka M, Okano M, Imaki J, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther. 1993;264:158-165. (Pubitemid 23309197)
5. Une T, Kurumiya S. Pharmacological profile of blonanserin. Jpn J Clin Psychopharmacol. 2008;10:1263-1272.
6. Ishibashi T, Nishikawa H, Une T, et al. Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia. Nihon Yakurigaku Zasshi. 2008;132:351-360.
7. Yang J, Bahk WM, Cho HS, et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010;33:169-175.
8. Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010;71:1131-1137.
9. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology. 2008;33:3111-3125.
10. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
11. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520. (Pubitemid 30191189)
12. Nordstrom AL, Farde L,Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227-235. (Pubitemid 23091497)
13. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497-502.
14. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65:1491-1498.
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
16. Inada T, Yagi G. Current topics in tardive dyskinesia in Japan. Psychiatry Clin Neurosci. 1995;49:239-244. (Pubitemid 26020606)
17. Kane JM, Leucht S, Carpenter D, et al. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64(suppl 12): 5-19.
18. Ito H, Okubo Y, Halldin C, et al. Mapping of central D2 dopamine receptors in man using [11C]raclopride: PET with an anatomic standardization technique. Neuroimage. 1999;9:235-242. (Pubitemid 29369879)
19. Okubo Y, Olsson H, Ito H, et al. PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. Neuroimage. 1999;10:666-674. (Pubitemid 30026760)
20. Ito H, Sudo Y, Suhara T, et al. Error analysis for quantification of [11C]FLB 457 binding to extrastriatal D2 dopamine receptors in the human brain. Neuroimage. 2001;13:531-539. (Pubitemid 34185011)
21. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
22. Suhara T, Sudo Y, Okauchi T, et al. Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol. 1999;2:73-82.
23. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539. (Pubitemid 47301451)
24. Takano A, Suhara T, Ikoma Y, et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol. 2004;7:19-26. (Pubitemid 38523803)
25. Takano A, Suhara T, Kusumi I, et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:75-81. (Pubitemid 43021324)
26. Yasuno F, Suhara T, Okubo Y, et al. Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl). 2001;154:112-114. (Pubitemid 32186522)
27. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry. 1990;47:213-219. (Pubitemid 20086672)
28. Suhara T, Okubo Y, Yasuno F, et al. Decreased dopamine D2 receptor binding in the anterior cingulated cortex in schizophrenia. Arch Gen Psychiatry. 2005;59:25-30.
29. Talvik M, Nordstrom AL, Olsson H, et al. Decreased thalamic D2/D3 receptor binding in drug-naBve patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol. 2003;6:361-370. (Pubitemid 38146254)
30. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869-875. (Pubitemid 29260341)
31. Saruwatari J, Yasui-Furukori N, Inoue Y, et al. Effect of dose timing in relation to food intake on systemic exposure to blonanserin. Eur J Clin Pharmacol. 2010;66:899-902.
32. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008;197:229-235.
33. Halldin C, Farde L, Högberg T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med. 1995;36:1275-1281.
34. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics A review of the evidence. Neuropsychopharmacology. 1998;18:63-101. (Pubitemid 28026679)
35. Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic responseVa double-blind PET study in schizophrenia. Neuropsychopharmacology. 2007;32:1209-1215. (Pubitemid 46788848)
36. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology. 2005;30:2283-2289. (Pubitemid 41643981)
37. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology. 2006;31:1991-2001.
38. Farde L, Hall H, Pauli S, et al. Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse. 1995;20:200-208.
39. Kessler RM, Meltzer HY. Regional selectivity in clozapine treatment Am J Psychiatry. 2002;159:1064-1065.
40. Ito H, Arakawa R, Takahashi H, et al. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol. 2009;12:667-675.
41. Narendran R, Mason NS, May MA, et al. Positron emission tomography imaging of dopamine D2/D3 receptors in the human cortex with [11C]FLB 457: reproducibility studies. Synapse. 2011;65:35-40.